Urinary 8-isoprostane levels can indicate the presence, severity and extent of angiographic coronary artery disease

Acta Cardiologica

Volumn 63, Issue 4, 2008, Pages 415-422

  Basarici, Ibrahim ^a   Altekin, Refik Emre ^a,b   Demir, Ibrahim ^a   Yilmaz, Huseyin ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

^b Burdur State Hospital   (Turkey)

Author keywords

Atherosclerosis; Coronary artery disease; Gensini score; Isoprostane; Oxidative stress

Indexed keywords

8 ISOPROSTANE; C REACTIVE PROTEIN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PROTEIN URINE LEVEL; RISK ASSESSMENT; SCORING SYSTEM; VALIDATION STUDY;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DINOPROST; FEMALE; HEALTH STATUS INDICATORS; HUMANS; INFLAMMATION; LOGISTIC MODELS; MALE; MIDDLE AGED; OXIDATIVE STRESS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 52249121376     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.63.4.2033038     Document Type: Article

References (50)

1. George C, Logstrup S, eds. European cardiovascular disease statistics. 2005 edition, London: British Heart Foundation; 2005.
2. World Health Organisation. Preventing chronic diseases - a vital investment; WHO Global Report. World Health Organization; 2005.
3. Gaziano TA. Cardiovascular disease in the developing world and its cost-effective management. Circulation 2005; 112: 3547-53.
4. McMahan CA, Gidding SS, Malcom GT, Tracy RE, Strong JP, McGill HC Jr; Pathobiological Determinants of Atherosclerosis in Youth Research Group. Pathobiological determinants of atherosclerosis in youth risk scores are associated with early and advanced atherosclerosis. Pediatrics 2006; 118(4): 1447-55.
5. Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, Fayad Z, Budoff MJ, Rumberger J, Naqvi TZ, Shaw LJ, Faergeman O, Cohn J, Bahr R, Koenig W, Demirovic J, Arking D, Herrera VL, Badimon J, Goldstein JA, Rudy Y, Airaksinen J, Schwartz RS, Riley WA, Mendes RA, Douglas P, Shah PK; SHAPE Task Force. From vulnerable plaque to vulnerable patient: Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force Report. Am J Cardiol 2006; 98[suppl 2A]: 2H-15H.
6. Taylor AJ, Burke AP, O'Malley PG, Farb A, Malcom GT, Smialek J, Virmani R. A comparison of the Framingham risk index, coronary artery calcification, and culprit plaque morphology in sudden cardiac death. Circulation 2000; 101: 1243-8.
7. Naghavi M, Libby P, Falk E, Casscells SW, Litovs.ky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003; 108: 1772-8.
8. Schwartz RS, Bayes-Genis A, Lesser JR, Sangiorgi M, Henry TD, Conover CA. Detecting vulnerable plaque using peripheral blood: inflammatory and cellular markers. J Interv Cardiol 2003; 16: 231-42.
9. Ross R. Atherosclerosis: an inflammatory disease. N Eng J Med 1999; 340: 115-26.
10. Singh U, Jialal I. Oxidative stress and atherosclerosis. Pathophysiology 2006; 13: 129-42.
11. KB as a mediator of initial lesion development in atherosclerosis. Trends Mol Med 2003; 9: 549-57.
12. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham risk score: Implications for future risk assessment; results from a large cohort study in southern Germany. Circulation 2004; 109: 1349-53.
13. 2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000; 28: 505-13.
14. Cracowskia JL, Ormezzano O. Isoprostanes, emerging biomarkers and potential mediators in cardiovascular diseases. Eur Heart J 2004; 25: 1675-8.
15. Gensini GG. Coronary arteriography. In: Braunwald E (ed). Heart disease. WB Saunders Company, 1980: pages 308-62.
16. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606.
17. Ringqvist I, Fisher LD, Mock M, Davis KB, Wedel H, Chaitman BR, Passamani E, Russell RO Jr, Alderman EL, Kouchoukas NT, Kaiser GC, Ryan TJ, Killip T, Fray D. Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). J Clin Invest 1983; 71: 1854-66.
18. Montuschi P, Barnes PJ, Roberts LJ 2nd. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004; 18: 1791-800.
19. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 29-38.
20. Morrow JD, Award JA, Boss HJ, Blair IA, Roberts LJ 2nd. Non-cyclooxygenase derived prostanoids (F2-isoprostanes) are formed in-situ on phospholipids. Proc Natl Acad Sci USA 1992; 89: 10721-5.
21. Yang I.S. Oxidative stress and vasculay disease: Insights from isoprostane measurements. Clin Chem 2005; 51: 14-5.
22. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-8.
23. Davi G, Falco A, Patrono C. Determinants of F2-isoprostane biosynthesis and inhibition in man. Chem Phys Lipids 2004; 128: 149-63.
24. 2 isoprostanes during oxidation of human low density lipoprotein and plasma by peroxynitrite. Circ Res 1995; 77: 335-41.
25. Yura T, Fukunaga M, Khan R, Nassar GN, Badr KF, Montero A. Free radical generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells. Kidney Int 1999; 56: 471-8.
26. Abramson JL, Hooper WC, Jones DP, Ashfaq S, Rhodes SD, Weintraub WS, Harrison DG, Quyyumi AA, Vaccarino V. Association between novel oxidative stress markers and C-reactive protein among adults without clinical coronary heart disease. Atherosclerosis 2005; 178: 115-21.
27. Kotur-Stevuljevic J, Memon L, Stefanovic A, Spasic S, Spasojevic-Kalimanovska V, Bogavac-Stanojevic N, Kalimanovska-Ostric D, Jeliç-Ivanovic Z, Zunic G. Correlations of oxidative stress parameters and inflammation markers in coronary artery disease patients. Clin Biochem 2007; 40: 181-7.
28. 2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. Chem Phys Lipids 2004; 128: 165-71.
29. Vasalle C, Botto N, Andreassi MG, Berti S, Biagini A. Evidence for enhanced 8-isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease. Coron Artery Dis 2003; 14: 213-8
30. Vasalle C, Petrozzi L, Botto N, Andreassi MG, Zucchelli GC. Oxidative stress and its association with coronary artery disease and different atherogenic risk factors. J Intern Med 2004; 256: 308-15.
31. Wang B, Pan J, Wang L, Zhu H, Yu R, Zou Y. Associations of plasma 8-isoprostane levels with the presence and extent of coronary stenosis in patients with coronary artery disease. Atherosclerosis 2006; 184: 425-30.
32. 2-isoprostanes in human atherosclerotic lesions. J Clin Invest 1997; 100: 2028-34.
33. Gross M, Steffes M, Jacobs DR Jr, Yu X, Lewis L, Lewis CE, Loria CM. Plasma F2-isoprostane and coronary calcium score: The CARDIA Study. Clin Chem 2005; 51: 125-31
34. Weinbrenner T, Cladellas M, Isabel Covas M, Fitó M, Tomás M, Sentí M, Bruguera J, Marrugat J and the SOLOS Study Investigators. High oxidative stress in patients with stable coronary heart disease. Atherosclerosis 2003; 168: 99-106.
35. Elesber AA, Best PJ, Lennon RJ, Mathew V, Rihal CS, Lerman LO, Lerman A. Plasma 8-isoprostaglandin F2 alpha, a marker of oxidative stress, is increased in patients with acute myocardial infarction. Free Radic Res 2006; 40: 385-91.
36. Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman JM, Kontush A. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high density lipoprotein particles displaying impaired antioxidant activity. J Clin Endocrinol Metab 2004; 89: 4963-71.
37. Cavusoglu E, Chopra V, Gupta A, Ruwende C, Yanamadala S, Eng C, Clark LT, Pinsky DJ, Marmur JD. Usefulness of the white blood cell count as a predictor of angiographic findings in an unselected population referred for coronary angiography. Am J Cardiol 2006; 98: 1189-93.
38. Kaneda H, Taguchi J, Ogasawara K, Aizawa T, Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atheroscl 2002; 162: 221-5.
39. Moon JY, Kwon HM, Kwon SW, Yoon SJ, Kim JS, Lee SJ, Park JK, Rhee JH, Hong BK, Rim SJ, Kim HS. Lipoprotein(a) and LDL particle size are related to the severity of coronary artery disease. Cardiology 2007; 108: 282-9.
40. 2α as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 2004; 109: 843-8.
41. Shishehbor MH, Zhang R, Medina H, Brennan ML, Brennan DM, Ellis SG, Topol EJ, Hazen SL. Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. Free Radic Biol Med 2006; 41: 1678-83.
42. Coolen SAJ, van Buuren B, Duchateau G, Upritchard J, Verhagen H. Kinetics of biomarkers: biological and technical validity of isoprostanes in plasma. Amino Acids 2005; 29: 429-36.
43. Wang Z, Ciabattoni G, Creminon C, Lawson J, Fitzgerald GA, Patrono C, Maclouf J. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J Pharmacol Exp Ther 1995; 275: 94-100.
44. Helmersson J, Basu S. F2-Isoprostane excretion rate and diurnal variation in human urine. Prostaglandins Leukot Essent Fatty Acids 1999; 61: 203-5.
45. Gopaul NK, Halliwell B, Anggard EE. Measurement of plasma F2-isoprostanes as an index of lipid peroxidation does not appear to be confounded by diet. Free Radic Res 2000; 33: 115-27.
46. Richelle M, Turini ME, Guidoux R, Tavazzi I, Metairon S, Fay LB. Urinary isoprostane excretion is not confounded by the lipid content of the diet. FEBS Lett 1999; 459: 259-62.
47. 2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol 2007; 433: 113-26.
48. Tsimikas S. Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease. Am J Cardiol 2006; 98(suppl): 9P-17P.
49. Mintz GS, Painter JA, Pichard AD, Kent KM, Satler LF, Popma JJ, Chuang YC, Bucher TA, Sokolowicz LE, Leon MB. Atherosclerosis in angiographically "normal" coronary artery reference segments: an intravascular ultrasound study with clinical correlations. J Am Coll Cardiol 1995; 25: 1479-85.
50. 2t-isoprostane. Ann Epidemiol 2004; 14: 793-7.